Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,903 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference.
Toi M, Benson JR, Winer EP, Forbes JF, von Minckwitz G, Golshan M, Robertson JF, Sasano H, Cole BF, Chow LW, Pegram MD, Han W, Huang CS, Ikeda T, Kanao S, Lee ES, Noguchi S, Ohno S, Partridge AH, Rouzier R, Tozaki M, Sugie T, Yamauchi A, Inamoto T. Toi M, et al. Among authors: ohno s. Breast Cancer Res Treat. 2012 Dec;136(3):919-26. doi: 10.1007/s10549-012-2333-9. Epub 2012 Nov 11. Breast Cancer Res Treat. 2012. PMID: 23143284
A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer.
Iwata H, Masuda N, Ohno S, Rai Y, Sato Y, Ohsumi S, Hashigaki S, Nishizawa Y, Hiraoka M, Morimoto T, Sasano H, Saeki T, Noguchi S. Iwata H, et al. Among authors: ohno s. Breast Cancer Res Treat. 2013 Jun;139(2):441-51. doi: 10.1007/s10549-013-2573-3. Epub 2013 May 30. Breast Cancer Res Treat. 2013. PMID: 23715630 Free PMC article. Clinical Trial.
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
Enokido K, Watanabe C, Nakamura S, Ogiya A, Osako T, Akiyama F, Yoshimura A, Iwata H, Ohno S, Kojima Y, Tsugawa K, Motomura K, Hayashi N, Yamauchi H, Sato N. Enokido K, et al. Among authors: ohno s. Clin Breast Cancer. 2016 Aug;16(4):299-304. doi: 10.1016/j.clbc.2016.02.009. Epub 2016 Feb 11. Clin Breast Cancer. 2016. PMID: 26993216 Free article. Clinical Trial.
A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study.
Yamamoto Y, Iwata H, Ueno T, Taira N, Kashiwaba M, Takahashi M, Tada H, Tsugawa K, Toyama T, Niikura N, Hara F, Fujisawa T, Yoshinami T, Saji S, Takano T, Masuda N, Morita S, Toi M, Ohno S. Yamamoto Y, et al. Among authors: ohno s. Jpn J Clin Oncol. 2018 Sep 1;48(9):855-859. doi: 10.1093/jjco/hyy097. Jpn J Clin Oncol. 2018. PMID: 30020510 Clinical Trial.
Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm.
Takada M, Sugimoto M, Masuda N, Iwata H, Kuroi K, Yamashiro H, Ohno S, Ishiguro H, Inamoto T, Toi M. Takada M, et al. Among authors: ohno s. Breast Cancer Res Treat. 2018 Dec;172(3):611-618. doi: 10.1007/s10549-018-4958-9. Epub 2018 Sep 7. Breast Cancer Res Treat. 2018. PMID: 30194511
The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial.
Sagawa N, Ohno S, Hiratsuka T, Kondo N, Iwata H, Bando H, Ohyama T, Ishida M, Kono Y, Nakajima K, Empuku S, Nishikawa S, Irie Y, Inomata M, Kitano S. Sagawa N, et al. Among authors: ohno s. Breast Cancer Res Treat. 2019 Aug;176(3):625-630. doi: 10.1007/s10549-019-05164-5. Epub 2019 Feb 26. Breast Cancer Res Treat. 2019. PMID: 30806921 Clinical Trial.
2,903 results